Who
Maria C. Freire
Director
Company insider
Files Form 4 as: Director, Biogen; Director, Exelixis; Director, Alexandria Real Estate Equities.
In numbers
- Trades disclosed
- 57
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $5.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 20 Apr 2012
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —2,005 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —2,005 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $408K20,634 at $19.77 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $949K20,634 at $46.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,634 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,634 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $408K20,634 at $19.77 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $949K20,634 at $46.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | ARE Alexandria Real Estate EquitiesREITs | SEC FORM 4 Code A | —3,493 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | ARE Alexandria Real Estate EquitiesREITs | SEC FORM 4 Code A | —3,493 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —2,370 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,874 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,240 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $325K15,874 at $20.50 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $624K28,240 at $22.10 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.5M44,114 at $34.94 | filing |
| 15 Jan 2025filed 17 Jan 2025 | ARE Alexandria Real Estate EquitiesREITs | SEC FORM 4 Code A | —2,032 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Maria C. Freire; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.